| 4.88 0.75 (18.16%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.86  |
1-year : | 6.84 |
| Resists | First : | 5.01 |
Second : | 5.86 |
| Pivot price | 3.71 |
|||
| Supports | First : | 3.82 |
Second : | 3.08 |
| MAs | MA(5) : | 4.04 |
MA(20) : | 3.6 |
| MA(100) : | 3.07 |
MA(250) : | 2.92 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 84.8 |
D(3) : | 71.1 |
| RSI | RSI(14): 76.2 |
|||
| 52-week | High : | 6.9 | Low : | 1.69 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CELZ ] has closed It is unclear right now based on current values. 101.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.02 - 5.04 | 5.04 - 5.05 |
| Low: | 4.01 - 4.03 | 4.03 - 4.04 |
| Close: | 4.85 - 4.88 | 4.88 - 4.91 |
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Tue, 07 Oct 2025
Creative Medical Technology Holdings Congratulates Nobel Laureates and Highlights Recent Patents for ImmCelz™ Platform - Quiver Quantitative
Tue, 07 Oct 2025
Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs - The Manila Times
Tue, 07 Oct 2025
2 U.S. Patents for ImmCelz: Creative Medical advances supercharged Treg therapy for HF and T1D - Stock Titan
Wed, 13 Aug 2025
FDA Fast-Tracks Revolutionary Non-Opioid Back Pain Treatment, Targeting $20B Market - Stock Titan
Thu, 10 Jul 2025
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ): When Will It Breakeven? - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 2.18e+006 (%) |
| Held by Institutions | 1.3 (%) |
| Shares Short | 117 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.81e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -98 % |
| Return on Assets (ttm) | 656.7 % |
| Return on Equity (ttm) | -49.1 % |
| Qtrly Rev. Growth | 6000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -15.3 |
| EBITDA (p.s.) | 689.65 |
| Qtrly Earnings Growth | -3.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.32 |
| Price to Cash Flow | 9.61 |
| Dividend | 0 |
| Forward Dividend | 76220 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|